Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8230575 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 9 Pages |
Abstract
The Class I evidence of bevacizumab efficacy from the present study in the treatment of central nervous system radiation necrosis justifies consideration of this treatment option for people with radiation necrosis secondary to the treatment of head-and-neck cancer and brain cancer.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Victor A. M.D., Luc Ph.D., Ping Ph.D., Ashok J. M.D., Jeffrey S. Ph.D., B. Nebiyou Ph.D., Sujit M.D., Monica M.D., Mark R. M.D., Edward F. Ph.D.,